Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESMO 2019 | The Pitfalls of cell-free DNA sequencing

Geoffrey Oxnard • 28 Sep 2019
ESMO 2019
General

Geoffrey Oxnard, MD, Dana-Farber Cancer Institute, Boston, MA, discusses the downfalls of the use of cell-free DNA in the detection of cancer at the European Society for Medical Oncology (ESMO) 2019 congress in Barcelona, Spain.

More from Geoffrey Oxnard

3:41
Cell-free DNA for multi-cancer detection
Geoffrey Oxnard • 9 Apr 2020
2:54
Impact of COVID-19 on scientific research and treating patients
Geoffrey Oxnard • 9 Apr 2020
4:55
Cell-free DNA liquid biopsy in lung cancer
Geoffrey Oxnard • 9 Apr 2020
1:07
Cell-free DNA sequencing in the clinical setting
Geoffrey Oxnard • 28 Sep 2019

Related Videos

1:56
Phase I trial of trastuzumab deruxtecan and neratinib in HER2-altered tumors
Haeseong Park • 8 Apr 2024
2:45
Remaining challenges in treating solid tumors with CAR-Treg therapy
Leonardo Ferreira • 8 Apr 2024
2:01
Engineering chimeric antigen receptor regulatory T cells for treating cancer
Leonardo Ferreira • 8 Apr 2024
0:59
What challenges are there in using CAR-T cells for solid tumors?
Leonardo Ferreira • 8 Apr 2024
The content of VJOncology is intended for healthcare professionals